Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 20/20 | 1.00 |
| ▸ | CASP7 | P55210 | 15/20 | 1.00 |
| ▸ | CASP6 | P55212 | 3/20 | 0.76 |
| ▸ | CASP1 | P29466 | 1/20 | 0.76 |
| ▸ | CASP2 | P42575 | 1/20 | 0.75 |
| ▸ | CASP9 | P55211 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156846 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP6CASP1CASP2 | |
| SCHEMBL13925501 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP6CASP1CASP2 | |
| SCHEMBL4142889 | 0.94 | CASP3 (1.00) | CASP3CASP7CASP6CASP1CASP2 | |
| SCHEMBL4142884 | 0.94 | CASP3 (1.00) | CASP3CASP7CASP6CASP1CASP2 | |
| SCHEMBL4147675 | 0.89 | CASP3 (1.00) | CASP3CASP7CASP6CASP1 | |
| SCHEMBL13914619 | 0.89 | CASP3 (0.81) | CASP3CASP7CASP6CASP2CASP9 | |
| SCHEMBL6535555 | 0.87 | CASP3 (0.79) | CASP3CASP7CASP6CASP2CASP9 | |
| SCHEMBL6535944 | 0.87 | CASP3 (0.79) | CASP3CASP7CASP6CASP2CASP9 | |
| SCHEMBL4300791 | 0.87 | CASP3 (1.00) | CASP3CASP7CASP6CASP1CASP2 | |
| SCHEMBL5184400 | 0.87 | CASP3 (1.00) | CASP3CASP7CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | claimed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | claimed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | claimed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | claimed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-8329686-B2 | Isatin analogues and uses therefor | WASHINGTON UNIVERSITY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20090068105-A1 | ISATIN ANALOGUES AND USES THEREFOR | WASHINGTON UNIVERSITY IN ST. LOUIS | 2009-03-12 | — | — | US | disclosed |
| EP-1087663-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1087663-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999065451-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068105-A1 | ISATIN ANALOGUES AND USES THEREFOR | CASP7, CASP3, HASPIN | CASP3 2/4885CASP7 1/4885CASP6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.